Tesaro Volatile After Johnson & Johnson Suspends Enrollment In Prostate Cancer Trial

TESARO Inc TSRO shares are trading higher by $0.33 at $140.00 in Friday's session.

The stock fell out of bed around 10:00 a.m. ET, when Johnson & Johnson JNJ suspended enrollment of Tesaro's Niraparib Phase 2 prostrate cancer trial pending review of data collected.

In a matter of 16 minutes, Tesaro's stock swooned from the $139.00 area all the way to $125.05 before staging a dramatic rebound. The stock was struggling to recover until 11:00 a.m. when Wells Fargo came out and defended the issue.

At this time, the rebound off the low took Tesaro's stock within a few pennies of the session high ($140.74) but retreated to the $140.00 area.